Urological Cancer Therapeutics Drugs Market to Exceed USD 48bn by 2025

NEW YORK, Feb. 27, 2018 -- Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.57 billion by 2025 Says, Profshare Market Research; growing at a CAGR of 10.5% between 2017 and 2025.Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs. In male prostate cancer is more common of these malignancies. Basically in urological cancer there is the growth of abnormal tissues in bladder, prostate, penile, testicular or kidney. This abnormal growth of tissues is referred to as tumours, which even spreads into the surrounding tissues or muscles. In old age people, bladder cancer is common in men than women. Depending on stage of cancer, there are different signs and symptoms of a urological cancer. The major factors responsible for urological cancer including age are chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes, smoking, advances in health care services, rising use of hormone therapies. New product innovation and research and developments will fuel the market of urological cancer therapeutics drugs.

The urological cancer market is segmented into cancer type, treatment type, end-user, and geography. There are different types of urological cancers such as kidney, prostate, testicular and bladder cancer. On the basis of type of treatment, the market is divided into chemotherapy, hormonal therapy, and surgery & radiation therapy. Depending on end-user, the market is divided into hospitals, urological cancer medical research laboratory and others. Top players of this market are Novartis, Pfizer, Johnson & Johnson, Astra Zeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, GlaxoSmithKline plc, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare and Sanofi S.A.

Get Free Sample: https://www.profsharemarketresearch.com/sample/urological-cancer-therapeutics-drugs-market-research-report-sample/

Global Urological Cancer Therapeutics Drugs Market: End Users/Application Analysis

• Hospital
  
  
• Medical Research Laboratory

Global Urological Cancer Therapeutics Drugs Market: Product Type

• Xofigo (radium Ra 223 dichloride)
  
  
• Jevtana (cabazitaxel)
  
  
• Inlyta (axitinib)
  
  
• Votrient (pazopanib hydrochloride)
  
  
• Sutent (sunitinib malate)
  
  
• Zytiga (abiraterone acetate)
  
  
• Xtandi (enzalutamide)
  
  
• Opdivo (nivolumab)
  
  
• Provenge (sipuleucel-T)

Report Enquiry: https://www.profsharemarketresearch.com/enquiry/urological-cancer-therapeutics-drugs-market-research-report-enquiry/

Global Urological Cancer Therapeutics Drugs Market : Competitive Analysis

Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Urological Cancer Therapeutics Drugs Market:

• Novartis
  
  
• Pfizer
  
  
• Johnson & Johnson
  
  
• AstraZeneca
  
  
• Astellas
  
  
• Bristol-Myers Squibb
  
  
• Abbott Laboratories
  
  
• Celgene Corporation
  
  
• Dendreon Corporation
  
  
• Ferring Pharmaceuticals
  
  
• GlaxoSmithKline plc
  
  
• Indevus Pharmaceuticals Inc
  
  
• Ipsen
  
  
• Roche Healthcare
  
  
• Sanofi S.A.

Buy Report: https://www.profsharemarketresearch.com/buy/urological-cancer-therapeutics-drugs-market-research-report-buy-su/

Contact Us:

Mia Cox,

Email- [email protected]

Tel- 1-877-797-7295

www.profsharemarketresearch.com